These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36649363)

  • 21. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
    Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
    BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study.
    Desbiens LC; Sidibé A; Ung RV; Fortier C; Munger M; Wang YP; Bisson SK; Marquis K; Agharazii M; Mac-Way F
    Osteoporos Int; 2018 Oct; 29(10):2345-2353. PubMed ID: 29959497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multifactorial analysis of renal anemia-associated substandard hemoglobin levels and prevalence of anemia in patients on maintenance hemodialysis in Liaoning Province: a cross-sectional study.
    Yin S; Du Y; Guo Y; Guo G; Sun D; Yao L
    Ann Palliat Med; 2022 Dec; 11(12):3743-3754. PubMed ID: 36635999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study.
    Zhang C; Wang S; Zhao S; Zhang X
    Medicine (Baltimore); 2017 Nov; 96(45):e8664. PubMed ID: 29137107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.
    Scialla JJ; Parekh RS; Eustace JA; Astor BC; Plantinga L; Jaar BG; Shafi T; Coresh J; Powe NR; Melamed ML
    Am J Nephrol; 2015; 42(1):25-34. PubMed ID: 26287973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Lee J; Scialla JJ; Bansal N; Sondheimer JH; Chen J; Hamm LL; Ricardo AC; Navaneethan SD; Deo R; Rahman M; Feldman HI; Go AS; Isakova T; Wolf M;
    JAMA Cardiol; 2016 Aug; 1(5):548-56. PubMed ID: 27434583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteocalcin and Abdominal Aortic Calcification in Hemodialysis Patients: An Observational Cross-Sectional Study.
    Jia F; Wang S; Jing Y; Zhao H; Rong P; Zhang H; Lu W; Xue Y; Sun G
    Front Endocrinol (Lausanne); 2021; 12():620350. PubMed ID: 33815281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.
    Sugimoto H; Ogawa T; Iwabuchi Y; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):99-106. PubMed ID: 23355029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D.
    Zhang M; Yan J; Zhu M; Ni Z
    Ann Clin Lab Sci; 2015; 45(1):17-22. PubMed ID: 25696005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis.
    Knap B; Večerić-Haler Ž; Benedik M; Buturović-Ponikvar J; Ponikvar R; Bren AF
    Ther Apher Dial; 2013 Aug; 17(4):407-11. PubMed ID: 23931880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetate-free biofiltration to remove fibroblast growth factor 23 in hemodialysis patients: a pilot study.
    Cernaro V; Lucisano S; Canale V; Bruzzese A; Caccamo D; Costantino G; Buemi M; Santoro D
    J Nephrol; 2018 Jun; 31(3):429-433. PubMed ID: 28401422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphate control in reducing FGF23 levels in hemodialysis patients.
    Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
    PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
    Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of klotho gene polymorphism and the regulation of calcium-phosphate metabolism disorders in patients with end-stage renal disease.
    Zeng QY; Xia ZY; Tong YS; Sun L; Mou HB; Chen R; Bi GY; Liu CH
    Nephrology (Carlton); 2019 Oct; 24(10):1001-1008. PubMed ID: 30537427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.
    Asamiya Y; Yajima A; Shimizu S; Otsubo S; Tsuchiya K; Nitta K
    Osteoporos Int; 2015 Mar; 26(3):1017-28. PubMed ID: 25366373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients.
    Urena Torres P; Friedlander G; de Vernejoul MC; Silve C; Prié D
    Kidney Int; 2008 Jan; 73(1):102-7. PubMed ID: 17943081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGF 23, PTH and vitamin D status in end stage renal disease patients affected by VDR FokI and BsmI variants.
    Bouksila M; Kaabachi W; Mrad M; Smaoui W; El Kateb EC; Zouaghi MK; Hamzaoui K; Bahlous A
    Clin Biochem; 2018 Apr; 54():42-50. PubMed ID: 29458003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of plasma neutrophil gelatinase-associated lipocalin with parameters of CKD-MBD in maintenance hemodialysis patients.
    Jia XY; Wei K; Chen J; Xi LH; Kong XL; Wei Y; Wang L; Wang ZS; Liu YP; Liang LM; Xu DM
    J Bone Miner Metab; 2021 Nov; 39(6):1058-1065. PubMed ID: 34392464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of FGF-23 With Biochemical Markers and Bone Density in Chronic Kidney Disease-Bone Mineral Density Disorder.
    Hussain I; Tandi R; Singh G; Kaur G; Abhishek ; Dodda S; Patel D; Natarajan B; Maram T; Kedia A; Vempati R; Sahu S; Choubey U
    Cureus; 2023 Jan; 15(1):e33879. PubMed ID: 36812096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.